For adults with Chronic Idiopathic Constipation (CIC)

Help identify patients with CIC that may be seeking a different treatment approach

The checklist below may help determine whether your patients may be looking for something that works differently.

Patient ID Tool

For your patients with Chronic Idiopathic Constipation (CIC), this checklist may help uncover if a prokinetic treatment approach is right for them.

Want to save a copy of this checklist to use later? Download the checklist.

Have your patients...

Expressed frustration with recurring symptoms?

Had less than 3 complete
spontaneous bowel
movements per week?

Felt a sense of
incomplete evacuation?

Asked about
dosing frequency?

Stopped taking their
CIC medication as prescribed?

Colonic dysmotility could be a factor affecting your patients with Chronic Idiopathic Constipation (CIC).1

Consider a prokinetic approach for patients looking for a treatment that works differently.

Interested in learning about the
Mechanism of Action for Motegrity?

Not a real patient


Expand Collapse

Please expand for Indication and Important Safety Information.


  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis


Motegrity® (prucalopride) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.


Reference: 1. Dinning PG, Di Lorenzo C. Best Pract Res Clin Gastroenterol. 2011;25(1):89-101.